Hansa Biopharma Reaches a Crucial Milestone in Imlifidase Phase 2 Clinical Trial for Guillain-Barré Syndrome

Hansa Biopharma (Nasdaq Stockholm: HNSA), a trailblazer in the world of enzyme technology aimed at rare immunological conditions, proudly announces that enrollment for its phase 2 clinical trial of imlifidase in Guillain-Barré Syndrome (GBS) has been successfully completed. The study’s…